JHVEPhoto/iStock Editorial by way of Getty Photographs
Bristol Myers Squibb (NYSE:BMY) reportedly expects to launch 16 new merchandise by the top of the last decade, however will probably be on the lookout for smaller offers after its 2023 buying spree.
Bristol Myers CEO Christopher Boerner stated Monday that as an alternative of pursuing one other main takeover, the corporate can be on the lookout for licensing agreements, bolt-on offers, and partnerships to bolster its pipeline and portfolio, according to a Reuters report.
Boerner made his remarks on the annual JP Morgan Healthcare Convention in San Francisco. The corporate additionally reiterated its outlook of greater than $10B in new product gross sales in 2026.
Final yr, Bristol Myers agreed to purchase Mirati (MRTX) by means of a deal price as much as $5.8B. In December, it agreed to amass Karuna (KRTX) for $14B and RayzeBio (RYZB) for $4.1B.